Treatment
SGLT2 inhibitor clinical trials
We’re tracking 45 recruiting studies that include SGLT2 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07776054RecruitingPhase 4
SGLT2 inhibitor after heart shock for atrial fibrillation with heart failure
This study tests whether a diabetes drug called an SGLT2 inhibitor can help keep your heart in a normal rhythm after a procedure to shock it back into rhythm. It is for people with persistent atrial fibrillation and a type of heart failure where the heart is stiff.
Seoul, SeoulAges 19 years+ - NCT06668389RecruitingPhase 4
Testing a diabetes medicine for repaired tetralogy of Fallot
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
Hong KongAges 18 years+ - NCT06473844Recruiting
SGLT2 inhibitors for adults with sepsis
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
Hong Kong, Hong KongAges 18 years+ - NCT04286399RecruitingPhase 4
Prevention trial for heart outcomes in people with type 2 diabetes
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
SingaporeAges 40 years+ - NCT06142474RecruitingPhase 3
SGLT2 inhibitors for heart failure patients during ventilator weaning
This trial tests a heart failure medication (SGLT2 inhibitor) to help people with heart failure who are on a breathing machine (ventilator) get better and come off the machine faster. It is for patients with a specific type of heart failure where the heart pumps weakly (EF ≤ 40%).
TaipeiAges 20 years+ - NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT05770687Recruiting
Testing diabetes heart medicine soon after a heart attack
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
SeoulAges 19 years+ - NCT06838286Recruiting
Study of triple therapy for type 2 diabetes
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT02378805Recruiting
Alport syndrome registry to help delay kidney failure
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
Göttingen, Lower SaxonyAges Any age - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Yangcheon, SeoulAges 20–80 - NCT06753994RecruitingPhase 1
Continuous ketone monitoring in type 1 diabetes with SGLT2 inhibitors
This study tests a new sensor that continuously measures ketone levels in people with type 1 diabetes who are also taking SGLT2 inhibitors. It aims to see if the sensor can help prevent diabetic ketoacidosis.
Montreal, QuebecAges 18 years+ - NCT07157475Recruiting
Blood vessel complications after leg artery procedures with SGLT2 inhibitors
This study looks at how a type of medicine called SGLT2 inhibitors (used for diabetes, kidney disease, or heart issues) affects blood vessel complications in people who have had a leg procedure to improve blood flow. It compares patients taking the medicine to those who are not.
Wroclaw, Lower Silesian VoivodeshipAges 18 years+ - NCT06291155RecruitingPhase 4
How SGLT2 inhibitors work in the kidneys for type 2 diabetes
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
Ann Arbor, MichiganAges 18–80 - NCT06585761Recruiting
SGLT2 inhibitors for heart failure: effect on inflammation
This trial tests whether a type of diabetes medicine called SGLT2 inhibitors can lower inflammation and stress markers in people with heart failure. It may help reduce damage to the heart and improve symptoms.
Kafr ash ShaykhAges 18–80 - NCT04899479RecruitingPhase 4
SGLT-2 inhibitor after heart attack to improve heart recovery
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
SeoulAges 18 years+ - NCT07038356RecruitingPhase 3
Continuing empagliflozin during heart failure hospitalizations
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Jena, ThuringiaAges 18 years+ - NCT07174687RecruitingPhase 2
SGLT2 inhibitor for geographic atrophy
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
St Louis, MissouriAges 50 years+ - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT05669742RecruitingPhase 3
Empagliflozin plus olanzapine to reduce metabolic side effects
This trial tests whether adding empagliflozin to standard olanzapine treatment can improve metabolic problems (like blood sugar and cholesterol changes) that can happen with olanzapine in people with schizophrenia. If you qualify, you would be closely monitored for benefits and side effects.
TantaAges 18–65 - NCT03878706Recruiting
Testing diabetes medicines on heart risk and heart failure
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
Athens, AtticaAges 45–80 - NCT04447911RecruitingPhase 4
Empagliflozin for chronic low blood sodium in certain fluid states
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
WürzburgAges 18 years+ - NCT05057806RecruitingEarly Phase 1
Testing how ketones may affect heart benefits in type 2 diabetes
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
San Antonio, TexasAges 18–80 - NCT05345327RecruitingPhase 3
First diabetes pill to protect kidneys
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
Sydney, New South WalesAges 18 years+
What SGLT2 inhibitor is being studied for
Conditions with recruiting SGLT2 inhibitor studies.
Common questions
- Are there clinical trials studying SGLT2 inhibitor?
- Yes. Clin2 currently lists 45 recruiting studies that include SGLT2 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a SGLT2 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is SGLT2 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether SGLT2 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.